{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:25:03Z","timestamp":1793413503858,"version":"4.5.0"},"reference-count":116,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunosuppressants, targeted antibody therapies, and surgical splenectomy are amongst the treatment choices for immune\u2010mediated non\u2010malignant hematologic disorders, with infection being the most common non\u2010hematological adverse event from these therapies. Corticosteroids are associated with a length\u2010of\u2010treatment and dose\u2010dependent risk for infection, including opportunistic infections. Screening and antimicrobial prophylaxis against tuberculosis,\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>Strongyloides stercoralis<\/jats:italic>\n                    <\/jats:styled-content>\n                    , and\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                    <\/jats:styled-content>\n                    pneumonia, are indicated in selected patients on steroids and with certain risk factors for infection. Rituximab is associated with hepatitis B virus reactivation. All patients planned to be started on rituximab should be screened for hepatitis B surface antigen and total core antibody, with antiviral prophylaxis given depending on test results. In eculizumab treated patients, immunization against meningococcal serogroups ACWY and B is recommended. In addition, some guidelines suggest antibiotic prophylaxis for the duration of eculizumab treatment. In splenectomized patients, counseling and immunization are cornerstones of infection prevention. Several federal and society guidelines about immunizations and prophylactic antimicrobial therapies for patients treated with various immunosuppressive agents exist and are summarized in this manuscript in a clinical\u2010focused table. In addition, management suggestions are made where no formal guidelines exist.\n                  <\/jats:p>","DOI":"10.1002\/ajh.25642","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T03:26:19Z","timestamp":1569900379000},"page":"1396-1412","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Preventing infectious complications when treating non\u2010malignant immune\u2010mediated hematologic disorders"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-1846","authenticated-orcid":false,"given":"Luis","family":"Malpica","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology University of North Carolina School of Medicine  Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases University of North Carolina School of Medicine  Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Moll","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology University of North Carolina School of Medicine  Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302984"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2936"},{"key":"e_1_2_12_5_1","unstructured":"Advisory Committee for Immunization Practices (ACIP). ACIP Meningococcal Vaccine Recommendations | CDC.https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/vacc-specific\/mening.html."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"e_1_2_12_7_1","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn AC","year":"2013","journal-title":"MMWR Recomm reports Morb Mortal Wkly report Recomm reports"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.2-5-440"},{"key":"e_1_2_12_9_1","unstructured":"KottonC\u2010C. Immunocompromised Travelers \u2010 Chapter 8\u20132018 Yellow Book | Travelers' Health | CDC.2017.https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2018\/advising-travelers-with-specific-needs\/immunocompromised-travelers."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23930"},{"key":"e_1_2_12_11_1","unstructured":"IDSA. IDSA : Patients Receiving Eculizumab (Soliris\u00ae) at High Risk for Invasive Meningococcal Disease Despite Vaccination. 2017.https:\/\/www.idsociety.org\/Breaking_News_and_Alerts\/CDC_HAN\/Patients_Receiving_Eculizumab_(Soliris\u00ae)_at_High_Risk_for_Invasive_Meningococcal_Disease_Despite_Vaccination\/."},{"key":"e_1_2_12_12_1","unstructured":"CDC. General Best Practice Guidelines for Immunization: Altered Immunocompetence.https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/immunocompetence.pdf."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1314291"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S52008"},{"issue":"3","key":"e_1_2_12_15_1","first-page":"134","article-title":"Should immunocompromised patients have pets?","volume":"8","author":"Steele RW","year":"2008","journal-title":"Ochsner J"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"e_1_2_12_17_1","unstructured":"ChathamW.Glucocorticoid effects on the immune system \u2010 UpToDate.2019.https:\/\/www.uptodate.com\/contents\/glucocorticoid-effects-on-the-immune-system."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.004"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3453"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002024"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e3181607262"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc3488"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1702.101020"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201205-0825OC"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000215"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21705"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/030097402760375205"},{"key":"e_1_2_12_28_1","unstructured":"fda cder. PREDNISONE \u2010 Highlights of Prescribing Information.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202020s000lbl.pdf."},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-78"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.009"},{"key":"e_1_2_12_31_1","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm reports Morb Mortal Wkly report Recomm reports. 2000;49(RR\u20106):1\u201351.http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10881762."},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00107608"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4472"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12410"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2293-4"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088096"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-693689"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12973"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060517695646"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.58.530"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009860"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.06.006"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.2479.2479"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20428"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/RMV.1984"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i21.2344"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601699"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2014.00033"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JMII.2011.12.020"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl16434"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e19039"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29344"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15892.1"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30040-1"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-018-0615-7"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2017.52.4.254"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181f2caef"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.635"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.892541"},{"key":"e_1_2_12_60_1","unstructured":"FDA. RITUXIMAB: Highlights of Prescribing Information.;2018.www.fda.gov\/medwatch."},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200306263482620"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21965"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2009.068940"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07715.x"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-178"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393975"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2014.07.214"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.003"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14841"},{"key":"e_1_2_12_71_1","unstructured":"US Food and Drug Administration (FDA). RITUXIMAB HIGHLIGHTS OF PRESCRIBING INFORMATION. 2012:40.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103705s5367s5388lbl.pdf."},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22882"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw222"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307827"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2018.0266"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848044"},{"key":"e_1_2_12_77_1","unstructured":"CDC Ncird. Immunology and Vaccine\u2010Preventable Diseases \u2013 Pink Book \u2013 Principles of Vaccination.https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/prinvac.pdf."},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-494096"},{"key":"e_1_2_12_79_1","unstructured":"fda cder. CYCLOPHOSPHAMIDE\u2010 FDA HIGHLIGHTS OF PRESCRIBING INFORMATION.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/012141s090 012142s112lbl.pdf."},{"key":"e_1_2_12_80_1","unstructured":"Fda Cder. IMURAN\u00ae (azathioprine)\u2010LABEL.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/016324s037 017391s016lbl.pdf."},{"key":"e_1_2_12_81_1","unstructured":"fda. CellCept\u00ae (mycophenolate mofetil capsules) \u2010label.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050722s021 050723s019 050758s019 050759s024lbl.pdf."},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23171"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAUT.2014.11.009"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344"},{"key":"e_1_2_12_85_1","unstructured":"FDA. Highlights of Prescribing Information\u2010Eculizumab (Solaris). 2011:1\u201324.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125166s172lbl.pdf."},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781450"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2408.180228"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S96720"},{"issue":"2","key":"e_1_2_12_89_1","first-page":"1024","article-title":"Hemolysis and septic shock with encapsulated bacteria in Eculizumab management of paroxysmal nocturnal hemoglobinuria","volume":"2","author":"Shi J","year":"2015","journal-title":"Ann Hematol Oncol"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2014.882712"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.21037\/sci.2017.12.04"},{"key":"e_1_2_12_92_1","unstructured":"Conseil sup\u00e9rieur d'hygi\u00e8ne publique de France. Personnes trait\u00e9es par Soliris\u00ae : actualisation des recommandations de vaccination et d'antibioprophylaxie.https:\/\/www.hcsp.fr\/Explore.cgi\/avisrapportsdomaine?clefr=447."},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv117"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264797"},{"key":"e_1_2_12_95_1","first-page":"2","article-title":"OPSI threat in hematological patients","volume":"6","author":"Serio B","year":"2013","journal-title":"Transl Med"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.54.3.214"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0904"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2015.057"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1198-743x.2001.00355.x"},{"key":"e_1_2_12_100_1","first-page":"1","article-title":"Prevention and control of haemophilus influenzae type B disease: recommendations of the advisory committee on immunization practices (ACIP)","volume":"63","author":"Briere EC","year":"2014","journal-title":"MMWR Recomm reports Morb Mortal Wkly report Recomm reports"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-15.3.152"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-603365"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-222448"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200204150-00027"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh445"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.11.005"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1191\/0961203302lu175cr"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1101\/131540"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000063"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12348-011-0041-y"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08854.x"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/11.5.677"},{"key":"e_1_2_12_113_1","unstructured":"fda. NEORAL\u00ae Soft Gelatin Capsules (cyclosporine capsules USP) MODIFIED NEORAL\u00ae Oral Solution (cyclosporine oral solution USP) MODIFIED.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050715s027 050716s028lbl.pdf."},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/941767"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2014.11.002"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-005-2032-4"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.11.004"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:12:44Z","timestamp":1785777164000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":116,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/ajh.25642"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25642","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"2019-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}